EUVIMEDEUVIMED entdecken
Open Access

Role of PARP and TRPM2 in VEGF Inhibitor‐Induced Vascular Dysfunction

Karla B Neves iD, Rheure Alves-Lopes, Augusto C Montezano, Rhian M Touyz iD

Journal of the American Heart Association · 21.02.2023 · 12 (4)

DOI: 10.1161/jaha.122.027769 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 21.02.2023. Verfasst von Karla B Neves und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cardiovascular and Medical Sciences University of Glasgow Glasgow United Kingdom. Hauptthemen laut MEDLINE: TRPM Cation Channels, Antineoplastic Agents, Neoplasms, Hypertension. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: British Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hypertension and vascular toxicity are major unwanted side effects of antiangiogenic drugs, such as vascular endothelial growth factor inhibitors (VEGFis), which are effective anticancer drugs but have unwanted side effects, including vascular toxicity and hypertension. Poly (ADP‐ribose) polymerase (PARP) inhibitors, used to treat ovarian and other cancers, have also been associated with elevated blood pressure. However, when patients with cancer receive both olaparib, a PARP inhibitor, and VEGFi, the risk of blood pressure elevation is reduced. Underlying molecular mechanisms are unclear, but PARP‐regulated transient receptor potential cation channel, subfamily M, member 2 (TRPM2), a redox‐sensitive calcium channel, may be important. We investigated whether PARP/TRPM2 plays a role in VEGFi‐induced vascular dysfunction and whether PARP inhibition ameliorates the vasculopathy associated with VEGF inhibition. Methods and Results Human vascular smooth muscle cells (VSMCs), human aortic endothelial cells, and wild‐type mouse mesenteric arteries were studied. Cells/arteries were exposed to axitinib (VEGFi) alone and in combination with olaparib. Reactive oxygen species production, Ca 2+ influx, protein/gene analysis, PARP activity, and TRPM2 signaling were assessed in VSMCs, and nitric oxide levels were determined in endothelial cells. Vascular function was assessed by myography. Axitinib increased PARP activity in VSMCs in a reactive oxygen species‐dependent manner. Endothelial dysfunction and hypercontractile responses were ameliorated by olaparib and a TRPM2 blocker (8‐Br‐cADPR). VSMC reactive oxygen species production, Ca 2+ influx, and phosphorylation of myosin light chain 20 and endothelial nitric oxide synthase (Thr 495 ) were augmented by axitinib and attenuated by olaparib and TRPM2 inhibition. Proinflammatory markers were upregulated in axitinib‐stimulated VSMCs, which was reduced by reactive oxygen species scavengers and PARP‐TRPM2 inhibition. Human aortic endothelial cells exposed to combined olaparib and axitinib showed nitric oxide levels similar to VEGF‐stimulated cells.

Conclusions

Axitinib‐mediated vascular dysfunction involves PARP and TRPM2, which, when inhibited, ameliorate the injurious effects of VEGFi. Our findings define a potential mechanism whereby PARP inhibitor may attenuate vascular toxicity in VEGFi‐treated patients with cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TRPM Cation ChannelsAntineoplastic AgentsNeoplasmsHypertensionHumansMiceAnimalsReactive Oxygen SpeciesVascular Endothelial Growth Factor APoly(ADP-ribose) Polymerase InhibitorsAxitinibEndothelial CellsNitric OxideAngiogenesis Inhibitors

Stichwörter der Autor:innen

PARPTRPM2VEGFvascular dysfunction

Substanzen

Reactive Oxygen SpeciesVascular Endothelial Growth Factor APoly(ADP-ribose) Polymerase InhibitorsTRPM Cation ChannelsAxitinibNitric OxideAntineoplastic AgentsAngiogenesis InhibitorsTRPM2 protein, humanTRPM2 protein, mouse

Autor:innen und Institutionen

  • Institute of Cardiovascular and Medical Sciences University of Glasgow Glasgow United Kingdom.
  • Strathclyde Institute of Pharmacy and Biomedical Sciences University of Strathclyde Glasgow United Kingdom.
  • Research Institute of the McGill University Health Centre (RI-MUHC) McGill University Montreal Canada.

ORCID-Profile: Karla B Neves, Rhian M Touyz

Förderung

  • British Heart Foundation

Zitieren

APA

Neves, K. B., Alves-Lopes, R., Montezano, A. C., & Touyz, R. M. (2023). Role of PARP and TRPM2 in VEGF Inhibitor‐Induced Vascular Dysfunction. Journal of the American Heart Association, 12(4). https://doi.org/10.1161/jaha.122.027769

Vancouver

Neves KB, Alves-Lopes R, Montezano AC, Touyz RM. Role of PARP and TRPM2 in VEGF Inhibitor‐Induced Vascular Dysfunction. Journal of the American Heart Association. 2023;12(4). doi:10.1161/jaha.122.027769

BibTeX
@article{Neves2023,
  author = {Neves, Karla B and Alves-Lopes, Rheure and Montezano, Augusto C and Touyz, Rhian M},
  title = {Role of PARP and TRPM2 in VEGF Inhibitor‐Induced Vascular Dysfunction},
  journal = {Journal of the American Heart Association},
  year = {2023},
  volume = {12},
  number = {4},
  doi = {10.1161/jaha.122.027769}
}
Kostenlos starten →